Lexicon Pharmaceuticals Inc

NASDAQ:LXRX  
3.45
+0.06 (+1.77%)
4:09:47 PM EDT: $3.47 +0.02 (+0.58%)
Products, Regulatory

Lexicon Submits NDA For Treatment Of Heart Failure In Type 2 Diabetes

Published: 12/30/2021 22:15 GMT
Lexicon Pharmaceuticals Inc (LXRX) - Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes.
Lexicon Submits New Drug Application for Sotagliflozin for Treatment of Heart Failure in Adults With Type 2 Diabetes.
Lexicon Pharmaceuticals Inc - NDA Submission is Supported by Results From Phase 3 Soloist Clinical Study.